C5 and lobular neoplasia: This was followed by studies that showed treatment success using eculizumab, a humanized anti-C5 monoclonal antibody, in an SLE patient with concomitant refractory TMA (12, 13, 44–46) and in LN patients with evidence of complement overactivation on kidney by finding of C9 deposition (46).